Rarebase Remarks: Chris Moxham - Drug hunting for rare disease

‍

Chris Moxham, PhD, is Chief Scientific Officer (CSO) at Rarebase. ​​Chris is a seasoned drug hunter with 25+ years of experience in large pharma and biotech. Prior to joining the Rarebase team, Chris was CSO at Fulcrum Therapeutics, a clinical stage biotech focused on rare diseases, where he was responsible for the full range of drug discovery, translational science and early development activities.

Learn more about what motivates Chris’s rare disease research efforts in our second episode of Rarebase Remarks.